NONALCOHOLIC FATTY LIVER DISEASE AND ITS COMPLICATIONS - ASSESSING THE POPULATION AT RISK. A SMALL SERIES REPORT AND LITERATURE REVIEW
Abstract
The aim of the study was to highlight correlations between serum biochemical markers and different degrees of liver inflammation or fibrosis revealed by liver biopsy in morbidly obese patients. We also wanted to emphasize that the occurrence of hepatocellular carcinoma (HCC) is increasingly associated with obesity, metabolic syndrome and nonalcoholic fatty liver disease. Material and methods: A clinical retrospective study was carried out on a series of 13 patients operated for morbid obesity in our surgical unit. Included in this study were only the obese patients referred for bariatric surgery without other risk factors for liver disease and in whom a liver biopsy was taken during metabolic surgery. Results: The pathology report revealed different stages of nonalcoholic fatty liver disease in all 13 patients: pathological features of steatohepatitis (7 patients), hepatic steatosis (5 patients) and lesions specific for evolving cirrhosis (1 patient). Regardless of the pathological changes of the liver, except the patient with evolving cirrhosis, none of these patients showed changes in classical liver function blood tests. Discussions: Hepatic alteration in obese patients, ranging from simple steatosis to steatohepatitis or even cirrhosis, is not always correlated with the values of classical biological liver function tests. Literature data suggest the involvement of adipokines in the development and progression of steatosis as the hepatic expression of metabolic and chronic inflammation syndrome occurring in obese patients. Furthermore, these proteins secreted by adipose tissue seem to be related to the HCC occurrence. However, none of these studies show the exact pathway followed by the hepatic cell from simple fatty liver to hepatocellular carcinoma. Conclusions: finding and selecting the population at risk for fatty liver disease progression and for HCC development among obese patients is mandatory.
References
2. State-specific prevalence of obesity among adults--United States, 2005. Mob Mortal Wkly Rep. 2006; 55: 985-992.
3. International Agency for Research on Cancer. GLOBOCAN 2008. Available from: URL: http://globocan.iarc.fr
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285.
6. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterol. 2011; 141: 1249-1253.
7. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001; 35: 531-537.
8. U.C. Nzeako, Z.D. Goodman, K.G. Ishak. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol, 1996;105 (1):65-75.
9. A. Sanyal, A. Poklepovic, E. Moyneur, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26(9): 2183-2191
10. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991; 115(12): 956-961.
11. Maximos M, Bril F, Portillo Sanchez P et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatol 2014. doi: 10.1002/hep.27395.
12. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7(4): 350-357.
13. Bugianesi E, Manzini P, D'Antrico S, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatol 2004; 39: 179-187.
14. M. Verdelho Machado, H. Cortez-Pinto. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol. 2014; 20(36): 12956-12980.
15. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syn-drome. J Clin Invest. 2004; 114: 1752-1761.
16. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013; 19: 5250-5269.
17. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steatohepatitis. J Hepatol. 2009; 50: 351-357.
18. Pietrangelo A. Metals, oxidative stress and hepatic fibrogenesis. Sem Liv Dis. 1996; 16: 13-30.
19. Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis 2011; 43: 89-95.
20. Cojocaru C, Trifan A, Stanciu C. Involvment and Role of Iron in Nonalcoholic Steatohepatitis. Rev Med Chir Soc Med Nat Iasi 2008; 112(2): 308-312.
21. Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, Kim M. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int. 2013;33:1100-1112.
22. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatol. 2005; 42: 1339-1348.
23. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunode-ficiency of malnutrition. FASEB J. 2001; 15: 2565-2571.
24. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-379.
25. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumor-igenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140: 197-208.
26. Stanciu C, Trifan A, Cojocariu I. Transient elastography an alternative to liver biopsy in patients with chronic hepatitis C? Rev Med Chir Soc Med Nat Iasi 2006; 110(4): 765-770.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
